CSF3 and Decreased total neutrophil count: Published models comprise for example pure pharmacokinetic models[25,46], pharmacokinetic and -dynamic models of G-CSF application on the cellular level[49], in healthy volunteers[50,51,70], for the treatment of cyclic neutropenia[71], for high-dose chemotherapy with stem cell transplantation[72,73] or for conventional chemotherapy patients[74,75].